Indaptus Therapeutics may sell up to $100,000,000 of common stock through H.C. Wainwright under an amended at-the-market agreement. For investors, the arrangement creates potential equity-raising capacity while leaving sales optional, subject to authorized shares, registration eligibility and transaction terms.

Key Highlights

  • The amended agreement dated August 28, 2026 supersedes the arrangement between Indaptus and Wainwright dated June 1, 2022.
  • An August 31 prospectus supplement supports the offer and sale of common stock under the amended agreement.
  • Indaptus will pay Wainwright a 3.0% Placement fee on shares sold as sales agent.

The arrangement gives the company a mechanism to raise Equity over time, although it is not required to sell shares and any sales remain subject to the agreement’s limits.

Wainwright Agreement Sets Sales Terms

The agreement was executed on August 28, 2026, and replaces the prior arrangement dated June 1, 2022. Wainwright may sell through applicable trading markets, market makers or privately negotiated transactions approved by Indaptus (NASDAQ: INDP).

Equity Sales Remain Optional

Indaptus has no obligation to sell common stock under the agreement, while either party may suspend the offering under its terms. Wainwright has agreed to use commercially reasonable efforts for agent sales but is not required to purchase shares as principal unless the parties separately agree. The company’s authority to issue shares remains subject to authorized but unissued stock, registration eligibility and other transaction conditions. The agreement states that the number, price and timing of any sales cannot be assured.

Peers Moving on This News